Please use this identifier to cite or link to this item:
|Title:||CCK receptors and cancer.||Austin Authors:||Baldwin, Graham S;Shulkes, Arthur||Affiliation:||University of Melbourne Department of Surgery, Austin Health, Heidelberg, Victoria, Australia||Issue Date:||2007||Publication information:||Current Topics in Medicinal Chemistry; 7(12): 1232-8||Abstract:||Over the past 20 years there has been considerable interest in the role of CCK receptors in gastrointestinal cancer. Initial excitement over reports of the detection by PCR of CCK-1 and CCK-2 receptor mRNA in a wide range of gastrointestinal tumours has been tempered by the realisation that the presence of receptor binding sites is much more restricted. The current consensus is that expression of CCK-1 and -2 receptor proteins is common only in tumours of neural or neuroendocrine origin. A striking example of this general rule has been provided by the detection of CCK-2 receptors by receptor autoradiography in more than 90% of medullary thyroid carcinomas. Despite the absence of CCK receptors from many gastrointestinal adenocarcinomas, evidence from animal models and from tumour cell lines in vitro suggests that the CCK-2 receptor may contribute to the development of esophageal and gastric adenocarcinomas, and further experimental work in these areas is clearly warranted. Promising therapeutic approaches include the development of radiolabelled gastrin/CCK derivatives for use in tumour imaging, and the use of appropriate selective antagonists for treatment of those tumour subtypes likely to express CCK receptors.||Gov't Doc #:||17584144||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10401||URL:||https://pubmed.ncbi.nlm.nih.gov/17584144||Type:||Journal Article||Subjects:||Animals
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.